# Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease

> **NCT02339415** · PHASE2 · COMPLETED · sponsor: **Hennepin Healthcare Research Institute** · enrollment: 44 (actual)

## Conditions studied

- Inflammation
- Coagulation
- HIV Infection

## Interventions

- **DRUG:** Edoxaban 30mg daily
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT02339415
- **Lead sponsor:** Hennepin Healthcare Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02339415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02339415, "Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02339415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*